ArticleCase reports in oncology
Rare Primary Hepatic Mucoepidermoid Carcinoma: A Report of Two Cases.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary mucoepidermoid carcinoma (MEC) of the liver is an extremely rare malignant tumor with nonspecific symptoms and signs. Case Presentation: The 2 cases included one Chinese male and one Chinese female, aged 72 and 47 years, respectively. Their clinical manifestations were hematemesis and upper abdominal pain. Imaging features were atypical, showing heterogeneous enhancement or cystic areas. After surgical resection, the pathological diagnosis was hepatic MEC, and the CRTC1-MAML2 fusion gene was found. Both patients did not undergo radiotherapy and chemotherapy after the operation, and died of tumor metastasis 3-4 months after tumor resection. Conclusion: Hepatic MEC is rare and has an extremely poor prognosis. Surgical resection is the main treatment, and diagnosis requires confirmation through histopathology, immunohistochemistry, and special staining. CRTC1-MAML2 fusion can also assist in diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.